Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › long QT syndrome

Long QT syndrome

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for long QT syndrome

7 trials tracked for long QT syndrome: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 7 citations.

7Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 2 1 Phase 1 1 Other / NA 3
  1. Phase 4 Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Completed · 7 cited
  2. Phase 4 Reducing the Risk of Drug-Induced QT Interval Lengthening in Women Completed
  3. Phase 2 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Completed
  4. Phase 1 Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function Completed
  5. N/A Fetal and Neonatal Magnetophysiology Completed
  6. N/A Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects Completed
Show 1 more trials
  1. N/A Long QT Syndrome and Sleep Apnea Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Long QT syndrome: what the trials found

Clinical investigations into the management of long QT syndrome have evaluated hormonal and placebo interventions. In studies assessing testosterone, a significant increase in maximum rate-corrected QT interval (QTF) was observed following ibutilide administration (p=0.001), although the percentage change from pretreatment values did not reach statistical significance (p=0.60) 1.

Progesterone administration also demonstrated a statistically significant increase in maximum post-ibutilide QT-F intervals (p=0.006). However, the percent change from baseline pre-ibutilide measurements was not significantly different (p=0.16) 2. Placebo groups showed no significant changes in QTc duration at either 2 months (p=0.7958) or 6 months (p=0.3369) 3.

Recent results — preliminary, needs further review

  • Eleclazine is currently under investigation in a Phase 1 trial 4.
  • Continuous Positive Airway Pressure (CPAP) was evaluated regarding baseline QT interval, but results were not statistically significant 5.
  • Magnetocardiography was assessed for symptom experience and adverse events; however, concordance with postnatal ECG for diagnosis of long QT syndrome was limited 6.

For the clinician treating this condition

  • Both testosterone 1 and progesterone 2 were associated with significant increases in maximum post-ibutilide QT intervals, though the magnitude of change from baseline did not reach statistical significance in either case.
  • Placebo interventions showed no statistically significant changes in QTc duration over a 6-month period 3.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Cardio-cerebral ion channel dysfunction links SUDEP and long QT syndrome in epilepsy patients
Neurology Sys. Review
Cardio-cerebral ion channel dysfunction links SUDEP and long QT syndrome in epilepsy patients Review suggests SUDEP and LQTS share a specific ion channel problem
This narrative review explores overlapping molecular mechanisms between sudden unexpected death in epilepsy (SUDEP) and long QT syndrome (LQ…
This review finds that sudden death in epilepsy may link to long QT syndrome through shared heart-brain electrical issues.
Frontiers Jun 7, 2026